MPI Research, in collaboration with the Global Cardiovascular Innovation Center, is proud to present

Advances in Therapeutic Discovery and Drug Development:

Cardiovascular Safety in Pharmaceutical and Medical Device Development

May 4–6, 2008
Brook Lodge in Augusta, Michigan

Internationally recognized academic, industry, and regulatory experts will present the latest in cardiovascular science, with particular focus on key safety issues related to the development of pharmacotherapeutics and devices.

Learn about the state of the art in current practices and possible future directions in preclinical cardiovascular safety assessment:
- Current themes
- Interrogation of potential safety targets
- Application of biomarkers
- Translation of preclinical models to the clinic

Gain knowledge of key issues in drug and device development, such as:
- Preclinical study design
- Common problems with drugs, devices, and combination products
- Opportunities for innovation/improvement
- “Acceptable” cardiovascular toxicities

You will have ample opportunity to engage in question-and-answer dialogues during the speaker sessions and in informal discussions with our panel of world-renowned experts about your own experiences with these compelling issues within a venue that is equally historic and beautiful.

Summit Fee
The summit fees include all meals and transportation to and from summit-related events. Lodging and transportation are not included in the summit fee. Transportation, via car service, from the Kalamazoo airport to Brook Lodge can be provided for a $25 fee.

Early registration fees: (received prior to March 28, 2008)
- $300 – Industry
- $200 – Academic

Registration
Space is limited, so early registration is encouraged. Registration must be received no later than April 15, 2008. There will be no on-site registration.

Register four ways:
- Mail or fax enclosed form (see back page)
- E-mail summit@mpiresearch.com
- Call 269.668.3336, ext. 3159
- Online at www.mpiresearch.com/summit_home08.asp

Visit www.mpiresearch.com for more information about the summit.
Welcome!

Dear Colleague,

Welcome to Southwest Michigan, home of the rapidly growing life sciences corridor of the Midwest! MPI Research welcomes this opportunity to collaborate with The Global Cardiovascular Innovation Center in bringing you this exciting summit!

Our distinguished panel of presenters is sure to stimulate as well as inform. Advances in the preclinical research process as they pertain to cardiovascular safety are impressive.

We believe you will enjoy this opportunity to both absorb and learn, as well as discuss the implications these cutting-edge presentations have on your own drug, biologic, and medical device development efforts.

Sincerely,

William U. Parfet, MBA
CEO
MPI Research

Ted Baird, PhD
Senior Director of Safety Pharmacology and Neurobehavioral Sciences
Summit Facilitator
MPI Research

Summit Facilitator

Ted Baird, PhD, is Senior Director of Safety Pharmacology and Neurobehavioral Sciences at MPI Research. Dr. Baird joined MPI Research as a Study Director in 2000, following completion of a research fellowship within the Department of Pharmacology at the University of Michigan, concentrating on neurobehavioral and cardiovascular pharmacology and pharmacokinetics of drugs of abuse. He received his master's and doctoral degrees from the Department of Psychiatry and Behavioral Sciences at the University of Oklahoma Health Sciences Center, with a focus in behavioral pharmacology and neuropharmacology. His research efforts have expanded into areas of preclinical neurobehavioral, cardiovascular, renal, and respiratory safety models, specifically as these models support pharmaceutical development efforts within the regulatory environment. Dr. Baird is an active member of the Safety Pharmacology Society and the American College of Toxicology, and author of more than 50 publications focusing primarily on topics related to cardiovascular and behavioral pharmacology.

Summit Co-Chairs

Mark Johnson, MS, is the Director of Surgery and Senior Study Director at MPI Research. He received his MS in neuropsychology from Eastern Michigan University in 1997. Prior to joining MPI Research in 2000, he was a research associate at the University of Michigan in the Department of Pharmacology and Neuroscience. From this background Mark brings years of experience in behavioral neuroscience, neuropharmacology, and surgical research to the MPI Research program. During his tenure with MPI Research, he has performed a wide variety of regulatory and non-GLP studies in multiple species and employing diverse surgical models. His areas of expertise include interventional cardiology with a focus on delivery, and evaluation of coronary and peripheral stents, neurology, and regenerative medicine.

E. Jon Popke, PhD, joined MPI Research in January 2006 and currently serves as Director of General Toxicology and Senior Study Director in the Divisions of General Toxicology and Safety Pharmacology. Dr. Popke received his PhD in medical psychology from the Uniformed Services University of the Health Sciences, Bethesda, Md, in 1997. Upon graduation he accepted a position with the U.S. Food and Drug Administration's National Center for Toxicological Research, where he managed a cooperative research and development agreement between the U.S. Food and Drug Administration and Astra-Zeneca. In 2001 Dr. Popke accepted a drug safety and development position with Wyeth Research, where he worked to design and conduct preclinical safety programs and to advance potential new pharmaceuticals toward registration in North America, the European Union, and Japan. Dr. Popke is a past president of the Behavioral Toxicology Society and serves as an ad hoc member of the Executive Committee of the African Society for Toxicological Sciences. He also sits on the Board of the Michigan Society for Medical Research and serves as a scientific reviewer for numerous professional journals.
Agenda

Sunday, May 4, 2008

Check-in
1 p.m. – 5 p.m.
Brook Lodge and Yarrow

Welcome Reception & Dinner
Reception 5:30 p.m.
Dinner 6:30 p.m.
Brook Lodge

Welcome Remarks by Ted Baird, PhD, Summit Facilitator &
Senior Director of Safety Pharmacology and Neurobehavioral
Sciences, MPI Research

Monday, May 5, 2008

Breakfast
7 a.m. – 8 a.m.
Brook Lodge

Keynote Address
Cardiovascular Care:
Current Perspectives and Future Opportunities
8 a.m. – 9 a.m.
Marc S. Penn, MD, PhD, FACC
Director, Bakken Heart-Brain Institute
Medical Director, Coronary Intensive Care Unit
Associate Director, Cardiovascular Medicine Fellowship
Departments of Cardiovascular Medicine and Cell Biology
Cleveland Clinic Foundation

Cardiovascular disease remains the leading cause
of morbidity and mortality in the Western world,
despite significant advances and successes
in the treatment of acute myocardial infarction,
coronary artery disease, and valvular heart disease.
The transition of the mortality associated with
cardiovascular disease from acute events to chronic declines
has led to the need for the identification of new targets and
development of new strategies for optimizing patient outcomes.
These new targets take the form of novel diagnostics as well as
modulators of disease-associated molecular pathways; therapies
involve devices, biopharmaceutical, and small molecules from
high-throughput molecular screens. However, at the same
time these new targets and strategies are being developed, we
need to optimize the current systems in an attempt to decrease
complications and adverse events and improve patient comfort,
risk, and cost. We will review the developments that have led to
significant advances in patient outcomes to date, review areas of
unmet clinical needs of patients with cardiovascular disease, and
discuss targets and strategies that may be developed to meet
these needs.

Preclinical Study Designs to Assess Pharmaceutical
Cardiovascular Liabilities
9 a.m. – 9:45 a.m.
Phillip R. Atterson, MSc
WIL Research Laboratories

Over the past 15 years there has been an increasing awareness
of liabilities associated with adverse cardiovascular effects of
pharmaceuticals that remained undetected until after approval
and marketing. Assessment of potential cardiovascular liabilities
associated with new pharmaceuticals has, therefore, become
more prominent and focused within the industry. Additionally,
we now have an extensive array of tools to assist us in our
evaluations, providing us with the ability to obtain a wide range
of cardiovascular parameter end points. Study designs based
on available technology and strategies to assess specific
liabilities will be discussed.

Break
9:45 a.m. – 10:15 a.m.
Refreshments served

Interrogation of Potential Targets for
Drug-Induced Cardiovascular Risk
10:15 a.m. – 11 a.m.
Robert L. Hamlin, PhD, DVM, DACVIM
(Cardiology/Internal Medicine)
The Ohio State University, QTest Labs

No risk assessment is complete unless effects on all targets of
cardiovascular function are interrogated. Although drug-induced
mortality is striking when it is manifested by unexpected sudden
death due to arrhythmia, it occurs rarely. In contradistinction,
morbidity and mortality probably occur orders of magnitude more
prevalently—but insidiously (over months or years)—from drug-
induced changes in non-electrophysiological properties (e.g.,
systemic arterial pressure, baroreceptor function). For example in
a META analysis, a 2 mmHg increase in systemic arterial pressure
translates to a nearly 10% increase in morbidity from stroke and a
similar increase in morbidity from heart failure. Drug-induced effects
on any or all of the properties of the cardiovascular system may
translate to morbidity and mortality. Excluding electrophysiological
properties, these properties are systemic arterial pressure
(peak, mean, pulsatile, diastolic), high pressure baroreceptor
function, hindrance to ejection (both impedance and resistance),
contractility, lusitropy, and myocardial energetics (ratio of oxygen
delivery to oxygen consumption). These properties may be
interrogated or inferred from manometry and echocardiography
in awake and/or anesthetized animals unperturbed and subjected
to either tilt or vasoactive drugs to alter baroreceptor loading.
Finally, since drugs are not given to normal persons and since
persons with disease (e.g., diabetes, heart failure, hypertension)
may have exaggerated drug effects, sensitivity for predicting
toxic manifestations in man may be increased—with only slight
compromise in specificity—by studying animals possessing
pathological states propitious for development of toxicity.
Selecting Clinically Predictive Assays in Assigning Cardiovascular Risk
11 a.m. – 11:45 a.m.
Anthony A. Fossa, PhD, DABT
iCardiac Technologies, Inc.

Establishment of models with validated sensitivities and caveats with regard to the pharmacokinetic/pharmacodynamic relationship of the clinical outcome is imperative for accurate early discovery decisions. Experimental models must be qualified using standards from the same mechanistic class. With novel agents where clinical outcomes have not been determined, this may be more difficult and affirmed only through receptor binding and in vitro drug metabolism studies in several species, including humans. Examples of several cardiovascular outcomes for prediction of blood pressure, heart rate, cardiac output, contractility, autonomic tone, and arrhythmia liability will be discussed.

Lunch
11:45 a.m. – 12:45 p.m.
Brook Lodge

The Life Sciences in Southwest Michigan
12:45 p.m. – 1 p.m.
Jerry Colca, PhD
President, Chief Scientific Officer and Co-Founder
Metabolic Solutions Development

Metabolic Solutions relocated from St. Louis to Kalamazoo in 2005 because of the strong life sciences cluster that exists in southwest Michigan. The company is developing innovative therapeutics using a different pharmacological path to treat diabetes and related symptoms of metabolic syndrome. Dr. Colca will provide a brief overview of the flourishing local life sciences sector.

Enabling Clinical Trials: Implications of Preclinical Safety Evaluations in Identifying Potential Cardiac Liabilities
1 p.m. – 1:45 p.m.
Richard J. Briscoe, PhD
Merck & Co., Inc.

This session will present the typical cardiovascular safety package required to enable Phase I and later stage clinical trials. A discussion of the importance of nonclinical cardiovascular signals and their translation to the clinic will be explored through the presentation of case studies. Finally, the utility of follow-up nonclinical investigations, which can result from a cardiovascular signal from later stage clinical trials, will be discussed.

Testing for Cardiac Arrhythmias in Preclinical Safety Pharmacology—What Works and What Can Be Improved?
1:45 p.m. – 2:30 p.m.
Craig T. January, MD, PhD
University of Wisconsin – Madison

Cardiovascular toxicity is a major problem in drug development, including altered cardiac electrophysiology and proarrhythmia. Most proarrhythmia results from drug interactions with the cardiac ion channel pore, and the ion channel of greatest concern is the hERG potassium channel. Existing preclinical screening approaches have been directed toward detecting hERG channel block, and alteration in cardiac action potentials and/or whole heart/animal electrophysiology. New cell-based mechanisms are being identified for cardiac proarrhythmia, including drug effects on ion channel biogenesis, drug effects on channels other than hERG, and drug effects on cell membranes and the ion channel macromolecular complex in which channels reside. This presentation will address limitations in cardiac arrhythmia preclinical safety pharmacology.

Break
3:30 p.m. – 3:45 p.m.
Refreshments served

Device Safety Testing—What Role Should It Play in Development?
2:30 p.m. – 3:15 p.m.
Nicholas Bari Olivier, PhD, DVM, DACVIM
Michigan State University

The role of safety testing in medical device development will be discussed. Issues will include regulatory requirements and conceptual issues comparing the benefits and limitations of animal model testing versus Phase I, II, or III clinical trials.

Preclinical Cardiac Device Models—What Works and What Can Be Improved?
3:15 p.m. – 4:15 p.m.
Gregory A. Kopia, PhD
Kopia Consulting

The safety evaluation of intravascular devices has traditionally been limited to local tissue effects. However, since the introduction of drug-eluting stents, safety evaluation has necessarily been expanded to include systemic effects as well. Local indices of tissue response such as thrombosis, inflammation, and necrosis continue to be useful in identifying safety issues with drug-eluting devices, while systemic pharmacokinetics are useful in identifying the potential for systemic toxicity. Long term effects of drug-eluting devices are particularly hard to identify in current animal models due to the absence of underlying disease and differences in the underlying animal vs. human pathobiology.
Reception & Dinner
6:30 p.m. – 10 p.m.
Gilmore Car Museum

Welcoming Remarks
William Harrison, President and COO, MPI Research

Tuesday, May 6, 2008

Breakfast
7 a.m. – 8:30 a.m.
Brook Lodge

Safety Concerns in the Development of Cell-Based Therapies for Myocardial Repair
8:30 a.m. – 9:15 a.m.
Bradley J. Martin, PhD
Aastrom Biosciences, Inc.

Interest in stem cell therapy as a means to repair damaged or diseased tissue has increased exponentially in the past decade. The specific application of stem cells in the treatment of myocardial infarction and failure has shown a great deal of promise in preclinical studies, and several human studies have been initiated. This presentation will focus on the myriad safety issues to be considered in moving such cell-based therapies from a research phenomenon to a clinically applicable therapy. Specifically, issues related to cell source, route of delivery, and the demonstration of cardiovascular safety will be discussed in the context of FDA submissions and guidance documents.

Understanding and Utilizing Bridging Biomarkers of Cardiovascular Toxicity
9:15 a.m. – 10 a.m.
Dana B. Walker, PhD, DVM, DACVP
Bristol-Myers Squibb

Recent withdrawals and box label warnings of marketed drugs due to human cardiovascular toxicity highlights potential deficiencies in conventional pre-market testing of this organ system. Newly available biochemical biomarkers that can directly bridge clinical and preclinical cardiovascular assessment may offer improved effectiveness of animal studies and clinical monitoring for toxicity of this system. Focusing on several of these biomarkers, including the cardiac troponins, FABP, NT pro-BNP, and markers of the procoagulant state, this discussion will cover what we know of their utility and interpretation, and what we still need to determine for their application as bridging biomarkers of toxicity across multiple species.

Break
10 a.m. – 10:30 a.m.
Refreshments served

When (and What) Is Acceptable Cardiotoxicity for a Drug?
10:30 a.m. – 11:15 a.m.
Shayne C. Gad, PhD, DABT, ATS
Gad Consulting Services

Drug-induced cardiotoxicity is an undesirable primary or secondary (or off-target) pharmacodynamic effect of a therapeutic agent. As such, its expression may take multiple forms (not limited to changes in cardiovascular electrophysiology and/or changes in rate and pressure), develop rapidly or only after protracted exposure, and be expressed differentially in different patient and nonclinical model populations. What constitutes both an adverse effect and the potential (and final) degree of acceptability of such an effect in a nonclinical model or patient population is somewhat situational and requires consideration of a number of factors, including therapeutic benefit, existence of alternative effective therapeutics, the incidence of unacceptable effects, and the therapeutic index for the drug in its target population.

Panel Discussion
11:15 a.m. – 12:15 p.m.

Closing Remarks
Summit Co-sponsors
MPI Research and The Global Cardiovascular Innovation Center

Lunch
12:30 p.m. – 1:30 p.m.
Brook Lodge
Speakers

Philip R. Atterson, MSc
Director, Pharmacology and Cardiovascular Sciences
WIL Research Laboratories
Ashland, Ohio

Mr. Philip Atterson received his MSc from the University of East London in the United Kingdom, with a focus in pharmacology. Mr. Atterson has more than 28 years of preclinical safety assessment experience in a contract research environment while satisfying global regulatory requirements. At WIL Research Laboratories, he is in charge of the direct technical and managerial oversight of the cardiovascular and pulmonary pharmacology laboratory. Mr. Atterson gained experience and knowledge in cardiovascular pharmacology through a number of roles of increasing responsibility in the Department of Pharmacology at Huntington Research Center, where he spent 18 years prior to joining Quintiles, where he held the position of Executive Director of Safety Pharmacology. He has had several publications and is an active member of the Safety Pharmacology Society.

Richard J. Briscoe, PhD
Associate Director
Merck & Co., Inc.
West Point, Pa

Richard Briscoe received his PhD from the University of Oklahoma Health Sciences Center in the Department of Psychiatry and Behavioral Sciences, with a research focus on cardiovascular and neuropharmacology. He then completed a postdoctoral research fellowship in the Department of Pharmacology at the University of Michigan Medical School. Following his appointment at the University of Michigan, Dr. Briscoe served as the Director of Safety Pharmacology at MPI Research. For the past five years Dr. Briscoe has led the in vivo Safety Pharmacology group at Merck & Co., Inc., and he is a member of the Merck Research Laboratories Cardiovascular Safety Team. He is a member of the Cordaptive™ product development team responsible for all aspects of the nonclinical safety assessment of this product. Cordaptive™ is Merck's investigational new drug for dyslipidemia. Dr. Briscoe is the Vice-President of the Safety Pharmacology Society and is a member of the British Journal of Pharmacology editorial board.

Jerry Colca, PhD
President, Chief Scientific Officer and Co-Founder
Metabolic Solutions Development
Kalamazoo, Mich

Dr. Jerry Colca has more than 30 years' experience in diabetes research. He has a BS in biology and an MS and PhD in biochemistry and physiology from the University of Houston, where he studied the regulation of secretion of pancreatic hormones. In his postdoctoral work at Washington University, he studied the biochemistry of isolated pancreatic islets and stimulus-secretion coupling in the control of metabolism. In 1984 he joined the Upjohn Company, where he led a research team that developed pioglitazone hydrochloride (Actos®). He remained a leader in diabetes discovery through several corporate mergers, retiring from Pfizer in 2005. Dr. Colca has published extensively on the mechanism of action of the insulin-sensitizing thiazolidinediones. In January 2006, he co-founded Metabolic Solutions Development Company.

Anthony A. Fossa, PhD, DABT
Consultant and Vice President for Cardiovascular Safety
iCardiac Technologies, Inc.
Rochester, NY

Dr. Anthony Fossa received his PhD from Purdue University, concentrating his studies in pharmacology and toxicology. Upon graduation, Dr. Fossa joined Pfizer and has been employed by them for more than 20 years. During his tenure with Pfizer, he has helped form the General Pharmacology group in Pfizer Discovery and has conducted in vivo preclinical cardiovascular assessments on over 150 clinical drug candidates. He is the Past President of the General Pharmacology Steering Committee and one of the original founders of the Safety Pharmacology Society. His research interests have been establishing in vivo models to differentiate proarrhythmic liability of drug candidates, with emphasis on the impact of changes in autonomic tone that affect the beat-to-beat electrocardiogram QT-TQ interval relationship and electrical alternans. As of April 2008, he will be retired from Pfizer as a Research Fellow to pursue translation of pharmacological safety data in humans as a consultant and Vice President of Cardiovascular Safety with iCardiac Technologies, Inc.

Shayne C. Gad, PhD, DABT, ATS
Principal
Gad Consulting Services
Cary, NC

Dr. Shayne Gad received his PhD from the University of Texas at Austin in pharmacology and toxicology. With more than 30 years of broad-based experience as a toxicologist, statistical consultant, manager, and consultant on research and development in the chemical, consumer product, contract testing, biotechnology, medical device, and pharmaceutical industries, Dr. Gad operates his own business, Gad Consulting Services. He brings years of experience in occupational and industrial toxicology; development programs (both preclinical and clinical) and study design, conducting and reporting, as well as dealing with a wide range of US and foreign regulatory bodies, commercial concerns, and contract research organizations to his more than 300 clients (including 120 pharmaceutical companies in the US and overseas). He is a member of several professional societies, including the American College of Toxicology, the Roundtable of Toxicology, and the Society of Toxicology. Dr. Gad is very well-published and has worked on more than 38 books, with more than 350 chapters, articles, and abstracts.

Robert L. Hamlin, PhD, DVM, DACVIM
Professor
College of Veterinary Medicine
The Ohio State University
Columbus, Ohio

Dr. Robert Hamlin received his PhD from The Ohio State University after becoming a Diplomate of Veterinary Medicine. He served consecutive research fellowships at the Central Ohio Heart Association and the National Institutes of Health. In 1960 Dr. Hamlin joined the Department of Veterinary Physiology and Pharmacology in the College of Veterinary Medicine at The Ohio State University and continues his employment there. He serves as a professor in the areas of cardiovascular physiology, comparative electrocardiography, and diseases of the cardiovascular system. Dr. Hamlin has more than 330 publications, with 20 selected book chapters. He is the Past President of the American College of Veterinary Internal Medicine and the Central Ohio Heart Chapter, Inc., a regional division of the American Heart Association. He is an active member of the American College of Veterinary Cardiology, the American Heart Association, and the American Physiological Society.

Craig T. January, MD, PhD
Professor, Department of Medicine, Division of Cardiovascular Medicine
Professor, Department of Physiology
University of Wisconsin School of Medicine and Public Health
Madison, Wis

Dr. Craig January received both his MD and PhD (Physiology and Biophysics) from the University of Iowa. Dr. January serves as a professor in the Departments of Medicine and Physiology at the University of Wisconsin – Madison. Prior to this role, he taught for 13 years at the University of Chicago. He is a Fellow of the American Heart Association and belongs to many organizations, including the American College of Cardiology, Biophysical Society, and the Cardiac Electrophysiology Society. Dr. January has an extensive publishing history with more than 200 papers and abstracts, and he serves as a reviewer of manuscripts and research grants for many journals and funding agencies. His research interests lie in congenital and acquired long QT syndrome and new therapies for these, triggered cardiac arrhythmias, modulation of ion channels, and the hERG potassium channel and IKr.

Dr. Anthony Fossa received his PhD from Purdue University, concentrating his studies in pharmacology and toxicology. Upon graduation, Dr. Fossa joined Pfizer and has been employed by them for more than 20 years. During his tenure with Pfizer, he has helped form the General Pharmacology group in Pfizer Discovery and has conducted in vivo preclinical cardiovascular assessments on over 150 clinical drug candidates. He is the Past President of the General Pharmacology Steering Committee and one of the original founders of the Safety Pharmacology Society. His research interests have been establishing in vivo models to differentiate proarrhythmic liability of drug candidates, with emphasis on the impact of changes in autonomic tone that affect the beat-to-beat electrocardiogram QT-TQ interval relationship and electrical alternans. As of April 2008, he will be retired from Pfizer as a Research Fellow to pursue translation of pharmacological safety data in humans as a consultant and Vice President of Cardiovascular Safety with iCardiac Technologies, Inc.
Dr. Gregory Kopia received his PhD from the University of Medicine and Dentistry of New Jersey, concentrating in pharmacology. He has conducted research in the biomedical community for more than 25 years. As a cardiovascular pharmacologist, he has conducted discovery and development research for both large and small companies, including GlaxoSmithKline, Johnson & Johnson, Zynaxis Cell Science, and Alkermes. His experience includes both pharmaceuticals and cardiovascular devices. His expertise encompasses many areas of cardiovascular therapeutic research and development, including antiarrhythmic agents, antanginal agents, thrombolitics, antithrombotics, agents for congestive heart failure, and intravascular stents. Most recently, as a Research Fellow of the Stent Therapeutics effort at Cordis Corporation, Dr. Kopia was credited as co-inventor of the CYPHER™ sirolimus-eluting stent, and his contribution was recognized with the awarding of the prestigious Johnson Medal. Dr. Kopia has authored and co-authored more than 90 publications, including full papers, abstracts, and book chapters, and he holds numerous patents. He currently is working as a consultant in his own business, where he is advising biotechnology companies and preclinical research organizations.

Dr. Marc Penn received both his MD and PhD from Case Western Reserve University in Cleveland, Ohio. Upon completing his medical degree and internal medicine residency, he was offered a Fellowship to the Cleveland Clinic Foundation Department of Cardiology, joining the Cleveland Clinic in 2000. Currently Dr. Penn serves as the Director of the Bakken Heart-Brain Institute, the Medical Director of Coronary Intensive Care Unit, Director of the Skirball Laboratory for Cardiovascular Cellular Therapeutics, and Associate Director of the Cardiovascular Medicine Fellowship in the Departments of Cardiovascular Medicine, Stem Cell Biology, and Biomedical Engineering. Dr. Penn is an active inventor and is named on several patent applications that are under review. He is the founder of AcelleRx Therapeutics and has contributed intellectual property to Prognostix, Inc., and Cardiomics, Inc. He is on the Scientific Advisory Boards of Oakwood Medical Investors and Frantz Medical Ventures. Dr. Penn's education and training have helped him develop drug delivery systems for the treatment of cardiovascular disease, including studies to optimize gene therapy and stem cell therapy for the regeneration of myocardial tissue. Dr. Penn continues his active involvement in the American Society of Gene Therapy, and the Arteriosclerosis, Thrombosis and Vascular Biology and the Basic Cardiovascular Sciences Councils of the American Heart Association. Dr. Penn has been an invited lecturer at international symposiums and conferences and has authored and co-authored numerous published articles, abstracts, book chapters, and books on a wide range of topics; including a recent publication of his book Stem Cells and Myocardial Regeneration, released in October 2006.

Dr. Dana Walker received an MS in Toxicology from Texas A&M and PhD in immunology, with a focus on immunotoxicology from North Carolina State University. She has combined veterinary pathology/clinical pathology residency training at Oklahoma State University and Texas A & M University. In June 2006, Dr. Walker joined Bristol-Myers Squibb, Pharmaceutical Research Institute as a Principal Veterinary Pathologist and director of their Syracuse-site Clinical Pathology Laboratory. Prior to joining Bristol-Myers Squibb, Dr. Walker served as a Principle Veterinary Pathologist at Wyeth Research Laboratories. She has served as co-chair of the ILSI-HESI Biomarkers Committee, Cardiac Troponins Working Group for the past four years and directly contributed to the working group’s analytical and biological validation of these and other cardiac injury biomarkers. She currently serves on committees in several other professional societies, including the American College of Veterinary Pathologists, the Society of Toxicology, and the Society of Toxicologic Pathologists.
Registration

Space is limited, so early registration is encouraged. Registration must be received no later than April 15, 2008. There will be no on-site registration.

Register four ways:

• E-mail summit@mpiresearch.com
• Call 269.668.3336, ext. 3159
• Online at www.mpiresearch.com/summit_home08.asp
• Mail or fax completed registration form to:
  Summit Registrar
  MPI Research
  54943 North Main Street
  Mattawan, MI 49071-9399 USA
  Fax 269.668.4151

NAME

TITLE

ORGANIZATION

STREET ADDRESS

CITY STATE ZIP COUNTRY

E-MAIL ADDRESS

CONTACT TELEPHONE

FAX

How did you hear about this summit?

Summit Fee

The summit fees include all meals and transportation to and from summit-related events. Lodging and transportation to and from Augusta, Michigan, are not included in the summit fee. Transportation, via car service, from the Kalamazoo airport to Brook Lodge can be provided for a $25 fee.

Received before March 28
$300 – Industry, $200 – Academic

Received after March 28
$400 – Industry, $300 – Academic

Payment

$ __________ Amount charged or enclosed

☐ Check in US dollar amounts made payable to:
  Summit Registrar

☐ Visa ☐ MasterCard ☐ Discover

PRINT NAME AS IT APPEARS ON CARD

CARD NUMBER EXPIRATION DATE

CARDHOLDER’S SIGNATURE

Accommodations

A limited number of rooms (first come, first served basis) will be available on the lovely grounds of Brook Lodge.

We also have reserved a block of rooms at the Yarrow Golf & Conference Center. Comfortable transportation to and from the summit site will be provided for you each day.

When your summit registration payment is received, lodging arrangements can be made directly with your preferred accommodations site.

Brook Lodge
Phone: 1.800.407.8486 or 1.269.731.2200
E-mail: lindst18@bl.msu.edu
Web Site: www.brooklodgmsu.com

Yarrow Golf & Conference Center
Phone: 1.800.563.4397
E-mail: yarrow.golf@tds.net
Web Site: www.yarrowgolf.com

Golf

For those who would like to arrange a round of golf at Yarrow, a beautiful course that preserves the natural surroundings, arrangements can be made for Sunday, May 4 (morning or afternoon). This well-designed course, with its rolling greens and dramatic views, challenges the best golfers and yet still leaves plenty of room for errant shots.

Cancellations

All cancellations will be subject to a $50 administration fee. In order to receive a prompt refund, your notice of cancellation must be received in writing by April 15, 2008. We regret that refunds will not be issued after this date. The registration may be transferred to another member of your organization. If you plan to send a substitute in your place, please notify us as soon as possible so that materials and preparations can be made. In the event a conference cancellation, MPI Research assumes no liability for non-refundable transportation costs, hotel accommodations, or additional costs incurred by registrants.